证券日报网讯 1月21日，福瑞医科在互动平台回答投资者提问时表示，截至2025年12月20日，福瑞医科 股东数量为24141户。 （文章来源：证券日报） ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Group 1 - The core point of the news is that Furuimei Medical has seen a continuous increase in its stock price, rising 0.79% to 84.15 CNY per share, with a total market capitalization of 22.298 billion CNY and a cumulative increase of 16.39% over the past six days [1] - Furuimei Medical, established on December 26, 2001, and listed on January 20, 2010, is primarily engaged in the production and sales of drugs in the liver disease sector, as well as the research and sales of medical instruments and medical services [1] - The company's revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Group 2 - According to data from the top ten holdings of funds, one fund under E Fund has a significant position in Furuimei Medical, with the E Fund Growth ETF (159572) holding 83,800 shares, representing 0.97% of the fund's net value [2] - The E Fund Growth ETF has generated a floating profit of approximately 55,300 CNY today and a total of 993,000 CNY during the six-day increase [2] - The E Fund Growth ETF was established on December 15, 2023, with a current scale of 644 million CNY and has achieved a year-to-date return of 11.1%, ranking 566 out of 5,520 in its category [2]

Group 1 - The core point of the article highlights the recent performance of Furuimei Medical, with a stock price increase of 12.72% over four consecutive days, reaching 81.50 CNY per share and a total market capitalization of 21.596 billion CNY [1] - Furuimei Medical, established on December 26, 2001, and listed on January 20, 2010, specializes in the production and sales of pharmaceuticals, instrument research and sales, and medical services, with revenue composition of 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Group 2 - The Hengsheng Qianhai High-end Manufacturing Mixed A Fund (013383) holds Furuimei Medical as its ninth largest position, with a current holding of 4,800 shares, representing 2.71% of the fund's net value [2] - The fund has seen a floating profit of approximately 12,480 CNY today, accumulating a total floating profit of 44,200 CNY during the four-day stock price increase [2] - The fund was established on June 29, 2022, with a current size of 9.0044 million CNY, and has achieved a year-to-date return of 4.82%, ranking 2,776 out of 9,012 in its category, and a one-year return of 85.8%, ranking 332 out of 8,157 [2]

Group 1 - The core viewpoint of the news is that Furuimei Medical has seen a continuous increase in its stock price, rising 12.72% over the last four days, with a current price of 81.50 yuan per share and a market capitalization of 21.596 billion yuan [1] - Furuimei Medical, established on December 26, 2001, and listed on January 20, 2010, is primarily engaged in the production and sales of drugs in the liver disease sector, as well as instrument research and sales, and medical services [1] - The company's revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Group 2 - According to data from the top ten holdings of funds, Chunhou Fund has a significant position in Furuimei Medical, with its Chunhou Times Preferred Mixed A Fund (014235) holding 10,000 shares, representing 3.78% of the fund's net value [2] - The Chunhou Times Preferred Mixed A Fund has generated a floating profit of approximately 9,200 yuan during the four-day price increase, with a current year-to-date return of 5.29% and a one-year return of 36.62% [2] - The fund manager, Chen Yin, has been in position for 185 days, with the fund's total asset size at 19.6662 million yuan, achieving a best return of 32.27% and a worst return of 31.96% during his tenure [3]

Core Viewpoint - The medical sector is experiencing significant activity, particularly driven by advancements in brain-computer interface (BCI) technology, which is attracting investor interest and leading to substantial market movements in related stocks and ETFs [3][10][11]. Market Performance - On January 6, 2026, the largest medical ETF (512170) saw a recovery, closing up 1.12% with a total trading volume of 1.017 billion yuan, marking two consecutive days of trading over 1 billion yuan [1][8]. - The ETF's index, which includes 12 related concept stocks, has a combined weight exceeding 36%, indicating strong sector representation [11][13]. Stock Highlights - Brain-computer interface stocks, such as Sanbo Brain Science and Meihua Medical, reached their daily limit up, while stocks like Yingke Medical and Hejing Biological experienced declines [1][8]. - The BCI sector is expected to see increased valuations for related listed companies, potentially boosting market financing and capital development [3][10]. Technological Advancements - A recent breakthrough in BCI technology was reported by Fudan University Huashan Hospital, which successfully completed the first clinical trial of a fully implanted, wireless, and functional BCI product [3][10]. - The BCI technology is positioned as a key area of investment, with potential applications in disease treatment and long-term enhancements for humans, opening up a market space worth trillions [10][11]. Investment Insights - According to CITIC Construction Investment, the current valuation of the medical index is 34.28 times, which is below the 70% threshold of the past decade, suggesting a favorable investment opportunity [4][11]. - The medical ETF (512170) is recognized as an efficient tool for accessing core medical assets, with a total size exceeding 26.4 billion yuan, making it the largest medical ETF in the market [6][13].

Core Viewpoint - Furuimei Medical experienced a stock price decline of 2.02% on January 6, 2025, with a trading volume of 331 million yuan and a total market capitalization of 19.065 billion yuan [1] Group 1: Stock Performance - As of January 6, 2025, Furuimei Medical's stock price was 71.95 yuan per share, with a year-to-date increase of 2.19% [1] - Over the last five trading days, the stock has decreased by 4.17%, while it has increased by 2.42% over the last 20 days and 4.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Furuimei Medical reported a revenue of 1.101 billion yuan, representing a year-on-year growth of 12.37% [2] - The net profit attributable to shareholders for the same period was 112 million yuan, reflecting a year-on-year increase of 9.69% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Furuimei Medical was 26,700, an increase of 3.24% from the previous period [2] - The average number of circulating shares per shareholder was 8,742, which decreased by 3.09% compared to the previous period [2] Group 4: Dividend and Institutional Holdings - Furuimei Medical has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the last three years [3] - As of September 30, 2025, major institutional shareholders included Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with notable changes in their holdings [3]

Group 1 - The core point of the article is that Furuimei Medical has announced the approval of several proposals at its first extraordinary general meeting of shareholders in 2026, including the issuance of H-shares and listing on the Hong Kong Stock Exchange [2] Group 2 - The company has passed a resolution regarding the issuance of H-shares and their listing on the Hong Kong Stock Exchange [2] - The company has also approved a plan for the use of funds raised from the issuance of H-shares [2]

证券代码：300049 证券简称：福瑞医科 公告编号：2026-001 内蒙古福瑞医疗科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议； 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项的参与度， 本次股东会对中小投资者单独计票。 一、会议召开情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：内蒙古福瑞医疗科技股份有限公司董事会 3、会议召开的合法性、合规性：经公司第八届董事会第十六次会议审议通过，决定 召开 2026 年第一次临时股东会，本次股东会的召开符合有关法律法规、深圳证券交易所 业务规则和公司章程等的规定。 4、会议召开的日期、时间： （1）现场会议时间：2026 年 1 月 5 日（星期一）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 1 月 5 日 9:15~9:25、9:30~11:30、13:00~15 ...

证券代码：300049 证券简称：福瑞医科 公告编号：2026-002 内蒙古福瑞医疗科技股份有限公司 关于独立董事及董事会专门委员会委员变更完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 内蒙古福瑞医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 5 日召开 2026 年第一次临时股东会，分别审议通过了《关于调整公司第八届董事会专门委员会委员的议案》 《关于选举公司第八届董事会独立非执行董事的议案》，现将相关情况公告如下： 一、独立董事的变更情况 为了完善公司治理结构，保证董事会规范运作、科学决策，经股东王冠一先生提名及提 名委员会资格审查通过后，公司于 2026 年 1 月 5 日召开 2026 年第一次临时股东会，审议通 过了《关于选举公司第八届董事会独立非执行董事的议案》，选举徐联义先生、花醒鸿先生 为公司第八届董事会独立非执行董事，任期自股东会审议通过之日起至第八届董事会任期届 满之日止；选举黄炜燊先生为公司第八届董事会独立非执行董事，任期自股东会审议通过且 公司发行的 H 股股票在香港联合交易所有限公司（以下简称"香港联 ...